Palliative care and hospice utilization in patients with relapsed or refractory diffuse large B-cell lymphoma in the era of CART and novel immunotherapies
{{output}}
Chimeric antigen receptor T-cell therapy (CART) has changed treatment for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), but most patients still die of their disease and may benefit from palliative care (PC) or hospice services. Whether CART av... ...
